| B28 | Loss of retinal nerve fiber layer and contrast sensitivity in people living with HIV with well controlled disease | E-poster | Other non-communicable diseases |
| B11 | Long-term survival and predictors of mortality in HIV/TB patients in Uganda | On-demand oral abstract session | Tuberculosis and other mycobacteria |
| C20 | Long-term survival among people living with HIV in rural South Africa: results from 6 years of observation in the ANRS 12249 treatment as prevention trial | E-poster | Measuring the population impact of prevention and treatment interventions |
| D15 | Long-term patterns of postpartum engagement in HIV care among women living with HIV in Cape Town, South Africa | E-poster | Retention in HIV services |
| B38 | Long-term efficacy among participants switched to bictegravir/emtricitabinetTenofovir alafenamide (B/F/TAF) from dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) with preexisting resistance and viral blips | E-poster | Antiretroviral drug resistance |
| B32 | Long-term analysis of B/F/TAF in treatment-naïve adults living with HIV through four years of follow-up | E-poster | ART in first- and second-line therapies |
| B33 | Long-term (96-week) safety of fostemsavir (FTR) in heavily treatment-experienced (HTE) adults infected with multidrug-resistant (MDR) HIV-1 (BRIGHTE Phase 3 study) | E-poster | ART in highly treatment-experienced people |
| B24 | Longitudinal study on insulin resistance and metabolic syndrome in children with perinatal HIV infection and HIV exposed uninfected children in South Africa | On-demand oral abstract session | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| A1 | Longitudinal alterations in O-linked glycosylation during chronic HIV-1 infection and its impact on V1/V2 & V3 targeting broadly neutralizing monoclonal antibodies | E-poster | Viral origins, evolution and diversity |
| B39 | Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) | Oral abstract session with live Q&A | Long-acting agents and other drug delivery systems |